The clinical information you need, at your fingertips.

Medical News for You

N Engl J Med

24m

EULAR 2026: New biologic halves flare risk in IgG4-related disease

Phase 3 INDIGO trial shows obexelimab reduces flares while sparing steroids. . .

Lancet

ADA 2026: Oral GLP-1 pill delivers strong A1c and weight-loss results in type 2 diabetes

In the phase 2b SOLSTICE trial, once-daily oral elecoglipron significantly improved glycemic control and reduced body weight. . .

JAMA Pediatr

Earlier egg introduction linked to lower infant egg allergy rates

Population-level Australian data suggest updated infant feeding guidance may be reducing egg allergy prevalence in young children. . .

Nat Med

New approach preserves lean mass during GLP-1 weight loss

Myostatin inhibition cut lean mass loss by more than half without reducing overall weight loss. . .

J Am Heart Assoc

21h

ADA 2026: Fewer deaths and clots observed with GLP‑1s in obesity with autoimmune disease

Real-world data show reduced thromboembolism, ED visits, and mortality with GLP‑1 therapy. . .

Ann Oncol

GLP-1 drugs linked to lower cancer risk in adults without diabetes

Large real-world study suggests meaningful reductions in obesity-related cancers beyond weight control. . .

Lancet

EULAR 2026: CD40L inhibitor improves lupus disease control in phase 3 trial

Dapirolizumab pegol significantly increased clinical response rates and showed steroid-sparing potential in patients with moderate-to-severe systemic lupus erythematosus. . .

ADA 2026

Monthly GLP-1 shows strong weight loss in phase 2b trials

Pfizer’s investigational berobenatide demonstrated substantial weight loss, HbA1c reductions, and favorable tolerability across weekly and monthly dosing regimens. . .

JAMA

Oral orforglipron improves glycemic control in insulin-treated type 2 diabetes

Up to 70% of patients achieved HbA1c below 7% without increased hypoglycemia risk. . .

The clinical information you need, at your fingertips.

EPOCRATES CME

Clinical FAQs